Bladder Cancer Clinical Trial

Follow up of Intravesical N-803 Plus BCG in BCG-Naive Non-Muscle Invasive Bladder Cancer (NMIBC)

Summary

The purpose of this clinical trial is to obtain long-term follow-up information and status of bladder cancer for patients who received study treatment in the QUILT-2.005 study.

View Full Description

Full Description

All 9 subjects that completed QUILT-2.005 phase 1b are planned to be enrolled in this study.

Thus, the maximum enrollment for this study is 9 subjects. All enrolled subjects will be followed every 12 months for life, or until withdrawal of consent, or if the Sponsor closes the study.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Enrolled and treated with intravesical N-803 plus BCG in the phase 1b portion of QUILT-2.005.

Exclusion Criteria:

Not applicable

Study is for people with:

Bladder Cancer

Estimated Enrollment:

6

Study ID:

NCT05981131

Recruitment Status:

Active, not recruiting

Sponsor:

ImmunityBio, Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Island Urology
Honolulu Hawaii, 96813, United States

How clear is this clinincal trial information?

Study is for people with:

Bladder Cancer

Estimated Enrollment:

6

Study ID:

NCT05981131

Recruitment Status:

Active, not recruiting

Sponsor:


ImmunityBio, Inc.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.